Novo Nordisk Faces FDA Warning Letter — Missed Death Reports Expose Pharmacovigilance Failure

FDA issues warning letter to Novo Nordisk over missing safety reports and death data gaps in pharmacovigilance systems, citing serious compliance breakdowns and increasing inspection risk.